Skip to main content

CORRECTION article

Front. Oncol. , 19 May 2023

Sec. Gastrointestinal Cancers: Hepato Pancreatic Biliary Cancers

Volume 13 - 2023 | https://doi.org/10.3389/fonc.2023.1218781

Corrigendum: The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway

This article is a correction to:

  1. The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway

    1. Read original article
Fuming Xie,,,&#x;Fuming Xie1,2,3,4†Yao Zheng,&#x;Yao Zheng4,5†Wen Fu,,,Wen Fu1,2,3,4Bojing Chi,Bojing Chi4,6Xianxing Wang,Xianxing Wang4,5Junfeng ZhangJunfeng Zhang4Jianyou GuJianyou Gu4Jingyang Yin,,,Jingyang Yin1,2,3,4Qiang Zhou,Qiang Zhou4,5Shixiang Guo,Shixiang Guo4,5Lei CaiLei Cai4Jiali Yang,*Jiali Yang4,5*Songsong Liu*Songsong Liu7*Huaizhi Wang,,,,*Huaizhi Wang1,2,3,4,5*
  • 1University of Chinese Academy of Sciences (UCAS) Chongqing School, Chongqing Medical University, Chongqing, China
  • 2Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences (CAS), Chongqing, China
  • 3Chongqing School, University of Chinese Academy of Sciences (UCAS), Chongqing, China
  • 4Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, University of Chinese Academy of Sciences (UCAS Chongqing), Chongqing, China
  • 5Chongqing Key Laboratory of Intelligent Medicine Engineering for Hepatopancreatobiliary Diseases, Chongqing General Hospital, Chongqing, China
  • 6Savaid Medical School, University of Chinese Academy of Sciences (UCAS), Beijing, China
  • 7Department of Hepatobiliary Surgery, Hainan Hospital of People’s Liberation Army of China (PLA) General Hospital, Sanya, China

A Corrigendum on
The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway

by Xie F, Zheng Y, Fu W, Chi B, Wang X, Zhang J, Gu J, Yin J, Zhou Q, Guo S, Cai L, Yang J, Liu S and Wang H (2023) Front. Oncol. 13:1138238. doi: 10.3389/fonc.2023.1138238

Error in Figure/Table

In the published article, there was an error in Figures 3D, F as published. The incorrect images were included. The corrected Figures 3D, F and its caption appear below.

FIGURE 3
www.frontiersin.org

Figure 3 METTL16 inhibits tumor growth in mice. (A) Nude mice were subcutaneously implanted with sh-NC or sh-METTL16 PC cells, and subcutaneous tumor nodules formed in the two groups of mice. (B) The weekly tumor volumes of the METTL16-knockdown and control groups are presented in the chart. (C) The mean tumor weights of the METTL16-knockdown and control groups 6 weeks after inoculation are presented. Two groups of tumor specimens were subjected to immunohistochemical detection of METTL16 (D, G), PCNA (E, H) and Ki67 (F, I). * means p<0.05; ** means p<0.01; *** means p<0.001.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: pancreatic adenocarcinoma, METTL16, m6A, p21, cell proliferation

Citation: Xie F, Zheng Y, Fu W, Chi B, Wang X, Zhang J, Gu J, Yin J, Zhou Q, Guo S, Cai L, Yang J, Liu S and Wang H (2023) Corrigendum: The m6A methyltransferase METTL16 inhibits the proliferation of pancreatic adenocarcinoma cancer cells via the p21 signaling pathway. Front. Oncol. 13:1218781. doi: 10.3389/fonc.2023.1218781

Received: 08 May 2023; Accepted: 09 May 2023;
Published: 19 May 2023.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2023 Xie, Zheng, Fu, Chi, Wang, Zhang, Gu, Yin, Zhou, Guo, Cai, Yang, Liu and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Jiali Yang, eGpfeWFuZ2ppYWxpQDE2My5jb20=; Songsong Liu, c29uZ3NsaXVAMTI2LmNvbQ==; Huaizhi Wang, d2h1YWl6aGlAZ21haWwuY29t

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Research integrity at Frontiers

Man ultramarathon runner in the mountains he trains at sunset

94% of researchers rate our articles as excellent or good

Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


Find out more